Cognition announces outcomes from trial of zervimesine for geographic atrophy
Cognition Therapeutics has announced positive topline outcomes from the double-masked Phase II MAGNIFY trial of zervimesine (CT1812) in adult patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).
The placebo-controlled study was completed following the enrolment of approximately 100 of the planned 246 subjects. It used two measures to assess the change in GA lesions: growth rate and size.
Subjects were evaluated for tolerability and safety, GA lesion size and growth rate changes, visual acuity changes, and other visual and anatomic measures.
According to the company, a slope analysis indicated that the GA trajectory had slowed by 28.6% in patients treated with zervimesine. In addition, at 18 months, the mean lesion size for those treated with zervimesine was 28.2% smaller than that of the placebo group.
Nearly two-thirds of subjects completed one year of dosing, and one-third completed 18 months.
While additional data on demographics, safety, and visual and anatomic outcomes are still under analysis, the company plans to present the complete findings at a medical meeting later in the year.
GA is marked by the formation of lesions consisting of dead retinal cells and undegraded waste proteins, leading to central vision blind spots.
In the trial, subjects were randomised and were given either a placebo or 200mg of oral zervimesine once a day.
The voluntary conclusion of the study enabled Cognition to redirect resources towards its ongoing Alzheimer's and dementia with lewy bodies (DLB) programmes.
Cognition Therapeutics research and development head and chief medical officer Anthony Caggiano said: 'To date, we have observed evidence of robust slowing of disease progression with zervimesine treatment in Phase II studies in Alzheimer's disease and dementia with Lewy bodies.
'These results in dry AMD represent yet another indication in which zervimesine has potential to slow the progression of disease with a once-daily oral pill. Compared to current treatment options, which require regular clinic visits for intravitreal injections, an effective oral treatment that patients can take at home would be truly transformative.'
In April last year, the company completed subject enrolment in its Phase II SHIMMER trial of CT1812 for treating mild-to-moderate DLB.
"Cognition announces outcomes from trial of zervimesine for geographic atrophy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
UCSD students protest Trump cuts to science research funding
SAN DIEGO (FOX 5/KUSI) — For the second time this year, students and faculty at the University of California, San Diego (UCSD) staged a protest outside Geisel Library, demanding the federal government reverse deep education funding cuts imposed by the Trump administration — cuts they say are threatening research, jobs and the future of scientific innovation. Dozens of protesters gathered on campus, holding signs and sharing personal stories about how the loss of federal research grants is impacting their work and well-being. Dozens possibly detained by federal officials amid immigration raids in Los Angeles 'This year has been filled with many moments of insecurity,' said Eleanor Ketterer-Sykes, a first-year Ph.D. student in the neuroscience program. 'UCSD is one of the best science schools in the country because of its renowned research labs, you have access to labs at the Salk Institute, Sanford and Scripps as well as the VA Hospital — but that future is in jeopardy.' The Trump administration has canceled hundreds of research grants in recent months, citing concerns over 'ideologically driven science.' The cuts have targeted studies ranging from HIV prevention to violence prevention in children. UCSD Chancellor Pradeep Khosla warned in an April letter that the university stands to lose between $75 million and $500 million annually as a result. 'As of May 30, there have been more than 150 federal grants terminated, resulting in a loss of $30 million,' said Lisa Eyler, a UCSD psychiatry professor. 'These cuts are already leading to layoffs among instructors, staff scientists, and support personnel like librarians.' 'No Kings Day' protests planned across California on June 14 The ripple effects could be felt beyond UCSD. Stanley Maloy, emeritus professor of microbiology at San Diego State University, said the cuts threaten the pipeline of future scientists and engineers. 'Reduced positions mean talented students are left behind,' Maloy said. 'As this innovation workforce dries up, our economy is going to suffer.' Eyler echoed those concerns, warning of a generational loss in scientific progress. 'There will be a gaping hole in the pipeline of future scientists, engineers and healthcare providers, which could result in the potential loss of an entire generation of great scientific thinkers,' she said. Thousands in San Diego protest cuts to federal education funds For Ketterer-Sykes, the issue is personal. She entered the neuroscience program hoping to make life-saving breakthroughs. 'So many people rely on scientific innovation — whether it be to find cures for diseases like tuberculosis or Alzheimer's disease,' she said. 'It really is vital to humanity.' While the exact financial toll remains uncertain, university leaders say the impact is already being felt — and may only get worse. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
5 hours ago
- Yahoo
Tips to take care of your brain for Alzheimer's and Brain Health Awareness Month
June is Alzheimer's and Brain Health Awareness Month and people hoping to spread that awareness said there are things you can do to take charge of your brain health. Brain changes that cause Alzheimer's can begin 20 years or more before symptoms appear. Work to start on Rockdale Road next week Doing things like exercising, eating right, getting good quality sleep, and controlling blood pressure can improve brain health and reduce the risk of cognitive decline. While age and family history are factors, these can naturally help you to reduce your risk. Millcreek man says over $1000 was stolen from EBT account 'It's not just the individual with the diagnosis, but it's the over 480 thousand caregivers here in the state of Pennsylvania that are providing that care. It's the family members that are in that circle of care who need that information and support. We want people to know they're not alone,' said Sara Murphy, vice president of programs and services for the Alzheimer's Association Greater PA Chapter. Early detection of cognitive diseases is crucial. The Alzheimer's Association also has a help line that anyone can call to get support at 1-800-272-3900. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
8 hours ago
- Yahoo
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) by anygal on r/investing on Reddit. In this article, we will summarize the bulls' thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)'s share was trading at $9.33 as of 30th May. ACOG's forward P/E was 26.88 according to Yahoo Finance. A chemist in a laboratory analyzing data from the various therapeutic tests conducted. Alpha Cognition Inc. (NASDAQ: ACOG) represents a potentially overlooked opportunity in the Alzheimer's treatment space, having recently launched its oral drug, Zunveyl, at the end of March. With a current market cap of $150 million and $45 million in cash, the company is targeting the underserved segment of the Alzheimer's population—specifically, the 50% of patients in long-term care (LTC) not taking any current medications due to severe side effects. Unlike other galantamine-based drugs, Zunveyl significantly slows disease progression and improves short-term memory with a markedly better safety profile—only one serious side-effect case was reported in its Phase 3 trials, versus a 50% rate seen in traditional options. The drug's Medicare coverage further eases affordability, lowering monthly out-of-pocket costs to $30–$190. Initial demand appears promising, with nearly 500 patients starting treatment in the first two weeks of launch. Even a modest 1% market penetration into the LTC segment could yield $135 million in annual revenue, with $67.5 million in net income assuming 50% margins. A 5% penetration would put net income at $675 million, dwarfing the current valuation. Alpha Cognition has also secured a distribution deal with a major Chinese pharmaceutical firm, creating a royalty-based revenue stream in Asia. While the upside is substantial, key risks remain—most notably, the emergence of unforeseen serious side effects post-launch, which could lead to FDA scrutiny or suspension of sales. Still, the market's underreaction and the company's positioning as a safer, effective alternative in a high-need space make ACOG a high-upside, high-conviction bet for risk-tolerant investors. Previously, we have covered ACOG in March 2025 wherein we summarized a by BullishDoctor on Twitter. The user highlighted that Alpha Cognition Inc.'s drug ZUNVEYL addressed the major side effects of existing Alzheimer's treatments, making it highly tolerable and poised for adoption in long-term care facilities, a $2 billion market. The company was pre-revenue but launched in March 2025 with strong physician support, a nearly complete sales force, and promising catalysts like a Phase 4 study and sublingual formulation, projecting breakeven within three years. Since our last coverage, the stock is up 61% as of 30th May. Alpha Cognition Inc. Common Stock (ACOG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held ACOG at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of ACOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
